Maxim Group set a $5.00 target price on Anavex Life Sciences (NASDAQ:AVXL) in a research report released on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on AVXL. ValuEngine lowered shares of Anavex Life Sciences from a hold rating to a sell rating in a research report on Tuesday, November 21st. Noble Financial reiterated a buy rating on shares of Anavex Life Sciences in a research report on Tuesday, December 12th.

Anavex Life Sciences (NASDAQ:AVXL) traded up $0.02 during trading hours on Wednesday, reaching $2.56. 223,100 shares of the company were exchanged, compared to its average volume of 323,922. Anavex Life Sciences has a 1 year low of $2.45 and a 1 year high of $6.49. The stock has a market cap of $113.22, a price-to-earnings ratio of -7.65 and a beta of 0.89.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, December 11th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). equities analysts forecast that Anavex Life Sciences will post -0.44 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Teachers Advisors LLC boosted its position in shares of Anavex Life Sciences by 5.7% during the 2nd quarter. Teachers Advisors LLC now owns 67,746 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 3,681 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Anavex Life Sciences by 12.1% during the 2nd quarter. Wells Fargo & Company MN now owns 40,385 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 4,347 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Anavex Life Sciences by 37.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 8,728 shares in the last quarter. Millennium Management LLC boosted its position in shares of Anavex Life Sciences by 95.2% during the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 21,895 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in shares of Anavex Life Sciences during the 2nd quarter worth $158,000. Institutional investors own 22.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Maxim Group Reiterates “$5.00” Price Target for Anavex Life Sciences (AVXL)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://theolympiareport.com/2018/02/15/maxim-group-reiterates-5-00-price-target-for-anavex-life-sciences-avxl.html.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.